Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Shares Issued (2020 - 2025)

Insight Molecular Diagnostics' Shares Issued history spans 5 years, with the latest figure at $29.1 million for Q1 2025.

  • For Q1 2025, Shares Issued changed N/A year-over-year to $29.1 million; the TTM value through Sep 2025 reached $39.3 million, up 148.93%, while the annual FY2024 figure was $26.0 million, 87.84% up from the prior year.
  • Shares Issued for Q1 2025 was $29.1 million at Insight Molecular Diagnostics, up from $10.2 million in the prior quarter.
  • Across five years, Shares Issued topped out at $65.3 million in Q1 2021 and bottomed at -$62.7 million in Q3 2021.
  • The 4-year median for Shares Issued is $13.0 million (2024), against an average of $15.7 million.
  • The largest YoY upside for Shares Issued was 759.05% in 2021 against a maximum downside of 6269000.0% in 2021.
  • A 4-year view of Shares Issued shows it stood at $62.7 million in 2021, then plummeted by 92.02% to $5.0 million in 2022, then surged by 104.1% to $10.2 million in 2024, then surged by 185.58% to $29.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Shares Issued are $29.1 million (Q1 2025), $10.2 million (Q4 2024), and $15.8 million (Q2 2024).